Dapoxetine

Overview

Dapoxetine is a short-acting selective serotonin reuptake inhibitor (SSRI) that represents the first compound in this drug class specifically developed and approved for the on-demand treatment of premature ejaculation (PE) in men aged 18-64 years. Unlike traditional SSRIs used for depression (fluoxetine, sertraline, paroxetine), which require weeks of daily dosing to achieve therapeutic effect and carry significant discontinuation syndrome risks, dapoxetine was designed with rapid absorption, rapid onset of action, and rapid elimination, enabling effective on-demand use 1-3 hours before sexual activity.

Dapoxetine was first approved in Sweden in 2009 under the brand name Priligy and has since gained regulatory approval in over 50 countries across Europe, Asia, Latin America, and Oceania. Notably, dapoxetine has not received FDA approval in the United States, where its new drug application has been subject to additional regulatory review. The global regulatory landscape reflects the complexity of evaluating a psychotropic drug administered on an as-needed basis rather than continuously.

Premature ejaculation is the most common male sexual dysfunction, affecting an estimated 20-30% of men across epidemiological studies. The ejaculatory reflex is primarily mediated by serotonergic neurotransmission in the brain and spinal cord, with serotonin (5-HT) acting as an inhibitory neurotransmitter at key nuclei in the ejaculatory pathway. This neurobiological basis provides the rationale for serotonergic pharmacotherapy in PE.

Mechanism of Action

Dapoxetine inhibits the serotonin transporter (SERT), blocking the reuptake of serotonin from the synaptic cleft into the presynaptic neuron. This increases serotonin concentration at postsynaptic receptors in neural circuits that modulate the ejaculatory reflex, thereby raising the threshold for ejaculation and increasing intravaginal ejaculatory latency time (IELT).

Ejaculatory Reflex Neuroanatomy

The ejaculatory reflex involves a spinal pattern generator located in the lumbar spinal cord, which integrates peripheral sensory input from the genitalia with descending modulatory input from supraspinal centers. Key brainstem nuclei involved include the nucleus paragigantocellularis (nPGi) in the medulla, which provides tonic serotonergic inhibition of the spinal ejaculatory generator. Serotonin acting at 5-HT2C receptors in the nPGi-spinal pathway delays ejaculation, while 5-HT1A autoreceptor activation reduces serotonin release and facilitates ejaculation. By increasing synaptic serotonin at these circuits, dapoxetine enhances 5-HT2C-mediated inhibitory tone over the ejaculatory reflex.

Rapid Pharmacokinetic Profile

Dapoxetine reaches peak plasma concentration (Tmax) approximately 1-2 hours after oral administration, with a terminal elimination half-life of approximately 1.4 hours for the parent compound. The rapid absorption and elimination kinetics distinguish dapoxetine from other SSRIs and enable on-demand dosing without the accumulation and discontinuation concerns associated with daily SSRI therapy. The initial elimination half-life is approximately 1.4 hours, followed by a terminal half-life of 15-19 hours, but the pharmacologically relevant plasma concentrations are achieved and cleared rapidly enough to support intermittent dosing.

5-HT Receptor Subtype Considerations

The acute increase in synaptic serotonin produced by dapoxetine acts primarily at postsynaptic 5-HT2C receptors to inhibit ejaculation. With chronic SSRI use, 5-HT1A autoreceptor desensitization occurs over 1-2 weeks, further enhancing serotonergic neurotransmission and explaining why daily SSRIs produce greater ejaculatory delay than single doses. Dapoxetine’s on-demand design accepts the trade-off of somewhat lesser efficacy compared to daily SSRIs in exchange for the practical advantage of intermittent dosing without daily medication burden.

Research Summary

Pryor et al. (2006) – Pivotal Phase III Trials

Pryor et al. (2006) published results from two identical, randomized, double-blind, placebo-controlled Phase III trials enrolling a combined total of 2,614 men with premature ejaculation in the Lancet. Participants received dapoxetine 30 mg, dapoxetine 60 mg, or placebo taken 1-3 hours before anticipated sexual intercourse. At 12 weeks, the geometric mean IELT increased from 0.9 minutes at baseline to 2.78 minutes with dapoxetine 30 mg and 3.32 minutes with dapoxetine 60 mg, compared to 1.75 minutes with placebo (p<0.001 for both doses vs. placebo). Patient-reported control over ejaculation, satisfaction with sexual intercourse, and personal distress related to ejaculation all showed statistically significant improvements with dapoxetine.

McMahon et al. (2011) – Integrated Analysis

McMahon et al. (2011) published an integrated analysis of five Phase III clinical trials evaluating dapoxetine in premature ejaculation. This comprehensive analysis of data from over 6,000 subjects confirmed dose-dependent efficacy, with dapoxetine 30 mg and 60 mg producing 2.5-fold and 3.0-fold increases in IELT, respectively, compared to 1.9-fold with placebo. The analysis also provided detailed safety data: the most common adverse events were nausea (8.7-20.1%), dizziness (5.8-10.9%), headache (5.6-8.8%), and diarrhea (3.5-6.9%). Discontinuation due to adverse events was 4% at 30 mg and 10% at 60 mg. No evidence of withdrawal syndrome, suicidality, or significant mood disturbance was identified with on-demand dosing.

Safety and Tolerability

Long-term safety studies of up to 24 months duration have confirmed that on-demand dapoxetine does not produce the withdrawal or discontinuation syndromes associated with daily SSRIs, supporting the safety of its intermittent dosing paradigm. The drug does not appear to cause significant changes in mood, anxiety, or sexual desire at approved doses.

Dosing in Published Research

Dapoxetine is a short-acting SSRI developed specifically for premature ejaculation. It is not approved by the FDA in the United States, but it is approved in numerous other countries (sold as Priligy and other brands). In its labeling and in the Phase 3 clinical trial program, dapoxetine is dosed on demand: a 30 mg starting dose taken approximately 1 to 3 hours before sexual activity, which may be increased to a maximum of 60 mg if the response is insufficient and tolerated. The Phase 3 trials evaluated 30 mg and 60 mg across more than 6,000 men. These figures are drawn from approved product labeling outside the US and from the published Phase 3 trial program.

Safety and Side Effects

Dapoxetine is a short-acting selective serotonin reuptake inhibitor (SSRI) developed specifically for premature ejaculation. Common adverse effects include nausea, dizziness, headache, diarrhea, and insomnia. A clinically important effect is orthostatic hypotension with the potential for syncope, or fainting, which can occur particularly after the first dose; this is why dapoxetine is taken on demand under specific precautions and is not recommended for people with significant cardiac disease. As an SSRI, dapoxetine carries class concerns including the risk of serotonin syndrome when combined with other serotonergic drugs, and it must not be used with, or close in time to, monoamine oxidase inhibitors. Mood changes and, rarely, suicidal thoughts are a recognized concern with serotonergic drugs.

Current Research Status

Dapoxetine is approved for the treatment of premature ejaculation in a number of countries in Europe and elsewhere, but it is not approved by the FDA and is not available as an approved product in the United States. It should be regarded as a prescription medicine appropriate only under medical supervision; material sold online outside regulated channels is of uncertain identity, dose, and purity.

Frequently Asked Questions